- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04140292
Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses
This study is open to individuals with Actinic Keratoses (skin lesions that have the potential to turn into skin cancer), who are receiving photodynamic therapy (PDT) as part of their clinical care. The purpose of this study is to test and demonstrate that vitamin D pre-treatment can enhance PDT efficacy in the treatment of Actinic Keratoses.
Participants will be asked to take vitamin D supplements prior to their standard of care PDT treatment.
Participation in the research will last about 3-4 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to determine whether acute supplementation (neoadjuvant Vitamin D3), adjusted according to baseline Vitamin D status, can improve the clinical PDT response relative to participants receiving PDT alone
The secondary objective of this study is to determine whether gene polymorphisms in VDR and CYP27B1 are predictive for the degree of responsiveness to Vitamin D as a neoadjuvant for PDT.
This study is a non-randomized interventional trial, in which the study group will be compared to a baseline cohort of patients from a previous study who received the same regimen of PDT, but without any Vit D. It is anticipated that 30 participants will be involved in this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Actinic keratoses in sufficient numbers (>10) to warrant PDT therapy in the clinic
- Able to understand and willing to sign a written informed consent document
Female subjects must not become pregnant during the study:
- The effects of 5-aminolevulinic acid (LevulanTM) on the human fetus are unknown. For this reason, women of child-bearing potential must agree to use contraception (double barrier method of birth control or abstinence) prior to study entry, and throughout study participation. Should a woman become pregnant or suspect that she is pregnant while she is participating in this study, she should inform the treating physician immediately.
Exclusion Criteria:
- Pregnant or nursing.
- At risk for hypercalcemia (renal disease, sarcoidosis, etc.)
- Using topical retinoids, since these can exacerbate the post-PDT erythema reaction.
- Using any topical treatment on their AKs; must stop at least one month prior.
- Currently undergoing treatment for other cancers with medical or radiation therapy.
- Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.
- Patients with history of a photosensitivity disease, such as porphyria cutanea tarda.
- Currently participating in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin D3 + Photodynamic therapy (PDT)
Patients receive Vitamin D3 10,000 IU daily for 5 or 14 days depending on VitD baseline level.
They then undergo Photodynamic therapy (PDT) for treatment of actinic keratosis.
|
PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered. D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months
Time Frame: 3 months after treatment
|
Clinical PDT response as measured by the percent change of AK lesions 3 months after treatment Baseline vitamin D (calcidiol) level will be taken for each patient. |
3 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation Between Vitamin D Receptor (VDR) Polymorphisms and Percent Reduction in AK
Time Frame: 3 months after treatment
|
Whether gene polymorphisms in VDR and CYP27B1 are predictive for the degree of responsiveness (as measured by percent reduction in AK) to Vitamin D as a neoadjuvant for PDT.
|
3 months after treatment
|
Number of Participants Reporting 1 or Higher on the Pain Scale
Time Frame: During treatment (at the 5 min mark), and again immediately afterwards.
|
Pain scale recorded on a 0-to-10 visual/analog scale, with higher scores mean more pain; 0 is no pain, 10 is "the worst pain imaginable".
Number of participants receiving treatment that reported a pain level greater than 1.
|
During treatment (at the 5 min mark), and again immediately afterwards.
|
Tolerability as Measured by Participants' Symptom Score Sheets
Time Frame: 1 week after treatment
|
Participants are asked to recall the symptoms they experienced during the week following PDT. The study physician asks them whether they had experienced each of the following 13 symptoms (YES/NO), and positive (YES) answers were summed to create a Side Effects Score (SES). The maximum and minimum possible values are 13 and 0 respectively, with a higher score correlating to poorer participant outcomes. The 13 possible side effects were: pain, erythema, scabbing, blistering, erosions, edema, warmth, exfoliation, discharge, hemorrhage, tightness, hyperpigmentation, hypopigmentation. |
1 week after treatment
|
Accumulation of Protoporphyrin IX (PpIX) Within AK
Time Frame: 3 months after treatment
|
Accumulation of protoporphyrin IX (PpIX) within AK PpIX accumulation in areas of both actinic damage and normal skin will be measured with a fluorescence dosimeter. The level of calcidiol, a clinically accepted marker of vitamin D status, will be measured in each patient to see if supplementation with 10,000 IU of Vitamin D increase the accumulation |
3 months after treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE5619
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on Photodynamic therapy (PDT)
-
Centre Hospitalier Universitaire de NiceWithdrawnDystrophic Epidermolysis BullosaFrance
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...Not yet recruitingPort-Wine Stain | Nevus Flammeus | Port-wine Birthmark
-
Biofrontera Bioscience GmbHRecruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustOndine Biomedical Inc.CompletedPeriodontitisUnited Kingdom
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Non-small Cell Lung Cancer | Stage 0 Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung CancerUnited States
-
First People's Hospital of HangzhouCompleted
-
Roswell Park Cancer InstituteCompletedRecurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the... and other conditionsUnited States
-
Biofrontera Bioscience GmbHActive, not recruitingSuperficial Basal Cell CarcinomaUnited States
-
Theralase Inc.University Health Network, Toronto; WCCT Global; Medelis Inc.CompletedNon-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCGCanada
-
Shahid Beheshti University of Medical SciencesCompletedBasal Cell Carcinoma